Recent cerebrospinal fluid biomarker studies of Alzheimer's disease

被引：23

作者：

Choi, Yong Seok ^{[1
,2
]}

Choe, Leila H. ^{[1
,2
]}

Lee, Kelvin H. ^{[1
,2
]}

机构：

[1] Univ Delaware, Dept Chem Engn, Newark, DE 19711 USA

[2] Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19711 USA

来源：

EXPERT REVIEW OF PROTEOMICS | 2010年 / 7卷 / 06期

关键词：

Alzheimer's disease; biomarker; cerebrospinal fluid; mass spectrometry; proteomics; QUALITY STANDARDS SUBCOMMITTEE; QUANTITATIVE-ANALYSIS; PROTEOMIC ANALYSIS; PROTEIN QUANTITATION; POTENTIAL BIOMARKER; PRACTICE PARAMETER; MASS-SPECTROMETRY; CSF; IDENTIFICATION; DEMENTIA;

D O I：

10.1586/EPR.10.75

中图分类号：

Q5 [生物化学];

学科分类号：

070307 [化学生物学];

摘要：

Alzheimer's disease is a progressive neurodegenerative disorder and the most common form of dementia. The disease is confirmed by the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex at autopsy, but the accuracy of antemortem diagnosis, especially at the early stages of the disease, is not ideal. Thus, there is a substantial need for the discovery and validation of diagnostic biomarkers. Many Alzheimer's disease biomarker discovery studies emphasize the analysis of cerebrospinal fluid (CSF) because of its close association with the brain. Here, we review recent mass spectrometry-based studies of Alzheimer's disease CSF, and additionally discuss issues associated with CSF in proteomics studies.

引用

页码：919 / 926

页数：8

共 59 条

[1]

Abdi F, 2006, J ALZHEIMERS DIS, V9, P293

[2]

Alzheimer's Association, 2009, 2009 ALZH DIS FACTS

[3]

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[4]

Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid [J].

Biroccio, A ;

del Boccio, P ;

Panella, M ;

Bernardini, S ;

Di Ilio, C ;

Gambi, D ;

Stanzione, P ;

Sacchetta, P ;

Bernardi, G ;

Martorana, A ;

Federici, G ;

Stefani, A ;

Urbani, A .

PROTEOMICS, 2006, 6 (07) :2305-2313

[5]

Methodological advances in the discovery of protein and peptide disease markers [J].

Bischoff, R ;

Luider, TM .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 803 (01) :27-40

[6]

CSF markers for incipient Alzheimer's disease [J].

Blennow, K ;

Hampel, H .

LANCET NEUROLOGY, 2003, 2 (10) :605-613

[7]

CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease [J].

Blennow, K ;

Vanmechelen, E ;

Hampel, H .

MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) :87-97

[8]

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease [J].

Blennow, Kaj ;

Hampel, Harald ;

Weiner, Michael ;

Zetterberg, Henrik .

NATURE REVIEWS NEUROLOGY, 2010, 6 (03) :131-144

[9]

Protein Quantitation through Targeted Mass Spectrometry: The Way Out of Biomarker Purgatory? [J].

Carr, Steven A. ;

Anderson, Leigh .

CLINICAL CHEMISTRY, 2008, 54 (11) :1749-1752

[10]

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects [J].

Castaño, EM ;

Roher, AE ;

Esh, CL ;

Kokjohn, TA ;

Beach, T .

NEUROLOGICAL RESEARCH, 2006, 28 (02) :155-163

← 1 2 3 4 5 6 →